title: [Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome].
abstract: The objective was to study efficacy and safety of ceraxon (citicoline) used perorally in dose 1000 mg daily in the treatment of cognitive disturbances in patients with amnesic type of mild cognitive impairment (MCI). Twenty patients, aged from 50 to 90 years, received ceraxon in dose 1000 mg twice a day during 90 days. The state of patients was assessed with a battery of scales and tests with the following statistical data analysis. The significant results on the clinical effect of the drug on cognitive disturbances and good tolerability of ceraxon have been obtained. The authors recommend ceraxon for long-term preventive treatment in high risk populations for Alzheimer's disease.
authors.forename: S I
authors.initials: SI
authors.lastname: Gavrilova
authors.forename: Ia B
authors.initials: IaB
authors.lastname: Fedorova
authors.lastname: Gantman
authors.forename: Ia B
authors.initials: IaB
authors.lastname: Kalyn
authors.forename: I V
authors.initials: IV
authors.lastname: Kolykhalov
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000517:prevention & control; D060825:Cognitive Dysfunction / Q000188:drug therapy*; D003566:Cytidine Diphosphate Choline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018697:Nootropic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013577:Syndrome
chemical_list: D018697:Nootropic Agents; D003566:Cytidine Diphosphate Choline